Efzofitimod 3 mg/kg

DRUG2 trials

Sponsors

aTyr Pharma, Inc.

Conditions

Pulmonary SarcoidosisSARS-CoV-2 (COVID-19) Severe Pneumonia

Phase 2

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

CompletedNCT04412668

aTyr Pharma, Inc.SARS-CoV-2 (COVID-19) Severe Pneumonia

Start: 2020-06-04End: 2020-10-23Updated: 2023-08-18

Phase 3

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

CompletedNCT05415137

aTyr Pharma, Inc.Pulmonary Sarcoidosis

Start: 2022-09-15End: 2025-07-14Updated: 2026-06-04

Related Papers

EFZO-FIT, Largest Placebo-controlled Trial in Pulmonary Sarcoidosis – Trial Design and Patient Characteristics

American Journal of Respiratory and Critical Care Medicine2025-05-012 citations

Exposure-response analyses of efzofitimod in patients with pulmonary sarcoidosis

Frontiers in Pharmacology2023-10-034 citations

Development and Characterization of a Novel Neuropilin-2 Antibody for Immunohistochemical Staining of Cancer and Sarcoidosis Tissue Samples

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy2023-10-015 citations